Scandion Oncology successfully completes the dose finding with lead compound SCO-101 in advanced pancreatic cancer patients (PANTAX phase Ib trial)
The trial’s primary endpoint was achieved, establishing the maximum tolerated dose of SCO-101 in combination with the standard chemotherapies gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer.
Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, has successfully completed the dose finding in the PANTAX phase Ib trial. The primary endpoint was achieved as the maximum tolerated dose of Scandion’s lead compound SCO-101 in combination with standard of care chemotherapies gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer was established at 200 milligrams given for 6 consecutive days every 2 weeks.
“We are delighted with these topline results both confirming that SCO-101 is safe and well-tolerated and establishing the maximum dose when employing the 6-day schedule explored in this combination. Further, we are pleased to have carried through the trial as another demonstration of our ability to conduct challenging international multicenter clinical trials aimed at tackling drug resistance in cancer”, says Alfredo Zurlo, M.D., Chief Medical Officer of Scandion.
Supports overall profile
The PANTAX topline results support the overall profile of SCO-101 as well-tolerated in combination with different chemotherapies in vulnerable patients.
A total of 22 patients with unresectable or metastatic pancreatic cancer were enrolled in the trial to receive SCO-101 treatment in combination with nab-paclitaxel and gemcitabine which is standard first- or second-line chemotherapy. Some patients still receive treatment with SCO-101 and chemotherapy and the full analysis of all safety and efficacy outcomes will be performed after all patients have completed treatment and a follow up-period.
Once the final data are available, Scandion will carefully analyze and publish the final results before deciding next steps of development of SCO-101 as a combination treatment of pancreatic cancer.
For further information please contact:
Johnny Stilou, CFO
Phone: +45 2960 3532
E-mail: [email protected]
This information is information that Scandion Oncology A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on March 31, 2023, at 10.00 CET.
Scandion Oncology (Scandion), the Cancer Drug Resistance Company, discovers and develops first-in-class medicines aimed at treating cancer which is resistant to current treatment options. We are at the forefront of this field, developing novel medicines that address cancer’s resistance against treatment. Our aim is to make existing cancer treatments work better and longer, thereby potentially prolonging and improving the life of patients who would otherwise have a high risk of dying from their cancer.
Globally, close to 10 million patients die every year from cancer and approximately 90 percent of all cancer related deaths are due to cancer drug resistance. Our medicines could be relevant in several different cancers. That makes both our medical and commercial potential significant.
Scandion is based in Copenhagen and its lead candidate, SCO-101, is currently being studied in clinical phase I and II trials. The company is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL).
Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market.
